Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Non-Current Deffered Revenue: 2024-2025

Historic Non-Current Deffered Revenue for Day One Biopharmaceuticals (DAWN) over the last 1 years, with Sep 2025 value amounting to $3.0 million.

  • Day One Biopharmaceuticals' Non-Current Deffered Revenue fell 3.53% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 million, marking a year-over-year decrease of 3.53%. This contributed to the annual value of $3.2 million for FY2024, which is N/A change from last year.
  • According to the latest figures from Q3 2025, Day One Biopharmaceuticals' Non-Current Deffered Revenue is $3.0 million, which was down 12.40% from $3.4 million recorded in Q2 2025.
  • Over the past 5 years, Day One Biopharmaceuticals' Non-Current Deffered Revenue peaked at $3.4 million during Q2 2025, and registered a low of $3.0 million during Q3 2025.
  • In the last 2 years, Day One Biopharmaceuticals' Non-Current Deffered Revenue had a median value of $3.2 million in 2024 and averaged $3.2 million.
  • Data for Day One Biopharmaceuticals' Non-Current Deffered Revenue shows a maximum YoY fell of 3.53% (in 2025) over the last 5 years.
  • Day One Biopharmaceuticals' Non-Current Deffered Revenue (Quarterly) stood at $3.2 million in 2024, then fell by 3.53% to $3.0 million in 2025.
  • Its Non-Current Deffered Revenue was $3.0 million in Q3 2025, compared to $3.4 million in Q2 2025 and $3.4 million in Q1 2025.